https://adisinsight.springer.com/drugs/800053722?error=cookies_not_supported&code=9ca65772-f3fa-4a12-99a5-19e16f5530c7
AVXS 501 - AdisInsight
AVXS 501, a gene therapy candidate is being developed by Novartis Gene Therapies (formerly AveXis, a subsidiary of Novartis) for the treatment of an undefined
adisinsight